If three or more significant and similar occurrences signify a trend, the U.S. hospitals that have closed in the heat of the COVID-19 crisis—mostly rural institutions—may be harbingers of things to come.

Such centers are the country’s largest providers of primary care and often cater to underserved patient populations and individuals without health insurance, the company noted. 

The COVID-19 pandemic has changed patient care in countless ways, but percutaneous coronary intervention (PCI) remains the recommended standard of care for ST-segment elevation myocardial infarction (STEMI) patients.

If the group’s actions are successful against the three entities named, unions representing healthcare workers elsewhere in the U.S. may be incentivized to take their cases to the courts in similar fashion.

The Amsterdam-based corporation, however, has seen a slight uptick in orders for imaging systems during the coronavirus crisis. 

That’s according to the results of a recent investigation, highlighted Monday in JAMA Internal Medicine.

Sometimes there’s real progress behind the slick pitch.

With so many eyes fixed on New York City as the “epicenter” of the COVID-19 crisis in the U.S., it might go unnoticed at the national level that nearly 60,000 infections could be recorded some 150 miles to the north by June 8.

Experts with the University of Michigan and RSNA recently explored such preparations in a new editorial, published in Radiology: Imaging Cancer. 

Newer-generation drug-eluting stents (n-DES) are a more effective option for the percutaneous treatment of small-vessel coronary disease (SVCD) than drug-coated balloons (DCBs), according to new findings published in JACC: Cardiovascular Interventions.